ArticleJAMIA open2026
Large language model-based triage to identify antiretroviral therapy adherence barriers and risk levels in patient messages.
Article in JAMIA open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to develop large language models (LLMs) to automatically identify antiretroviral therapy (ART) adherence barriers and stratify nonadherence risk levels from patient-generated messages. Materials and Methods: With a co-construction committee of people with HIV and providers, 15 480 sentences were annotated for barrier and risk levels. General-domain LLMs (eg, Flan-T5) and clinical foundation models (eg, Clinical-T5) were fine-tuned for multiclass classification and evaluated using Macro-F1. Best-performing models were compared with GPT family and other open-source LLMs. Model fairness, error patterns, and environmental footprints were also assessed. Results: Flan-T5-xl achieved the best barrier detection (Macro-F1 = 0.83 test/0.71 external), and Flan-T5-large excelled in risk stratification (0.79/0.57). Fine-tuned general-domain LLMs significantly outperformed clinical foundation models ( Discussion: Fine-tuned Flan-T5 models demonstrated strong classification performance, greater robustness to demographic attributes, and lower energy consumption, though challenges remained for subjective and underrepresented categories, reflecting both data imbalance and model limitations in implicit reasoning. Conclusion: LLM-based approaches show promise for real-time ART adherence monitoring, offering a scalable solution to individualized HIV care. Beyond performance, our findings highlight the importance of fairness and environmental sustainability in clinical AI development, with next steps focused on real-world validation through deployment in patient-facing digital tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.